Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Joins Fight against COVID-19, Eyes Plasma Product Launch in 9-18 Months
March 5, 2020
- Braftovi/Mektovi Filed for Colorectal Cancer in Japan: Ono
March 5, 2020
- Takeda Closes Non-Core Asset Divestment to Stada
March 5, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Asahi Kasei Completes Acquisition of Veloxis
March 5, 2020
- Sumitomo Dainippon Creates Chief Scientific Officer Post to Optimize Portfolio
March 4, 2020
- Shionogi’s Fetcroja Bags EU Panel Nod
March 4, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
- GE Healthcare Completes Takeover of Japan Licenses for 4 Imaging Agents from Daiichi Sankyo
March 4, 2020
- Kaken’s Efinaconazole Launched in Hong Kong
March 4, 2020
- Vital-Net to Create 20-Strong Team of “Regenerative Medicine Liaisons”
March 3, 2020
- Takeda’s ALK Drug Alunbrig Earns EU Backing for 1st Line NSCLC
March 3, 2020
- Takeda to Sell Latin American Non-Core Assets to Brazil’s Hypera Pharma
March 3, 2020
- Otsuka to Copromote Novartis’ Approval-Pending Entresto in Japan
March 3, 2020
- Sumitomo Dainippon Invests in Oncology Venture Fund
March 3, 2020
- Fujifilm’s US Subsidiary to Launch New iPS Cell Production Facility
March 3, 2020
- Toho Forges Capital Alliance with Kringle Pharma for Hepatocyte Growth Factor Development
March 3, 2020
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Crysvita Gets FDA’s Priority Review for Tumor-Induced Osteomalacia
March 2, 2020
- Takeda Files Midazolam Oral Solution for Status Epilepticus
March 2, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…